St. Jude PFO Program For Stroke, Migraine Gets Boost With Velocimed Deal
This article was originally published in The Gray Sheet
Executive Summary
St. Jude Medical will accelerate its patent foramen ovale (PFO) R&D program for stroke treatment by acquiring Velocimed for more than $82.5 mil. under a definitive agreement, the firms said Feb. 15